New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
07:07 EDTAUXLAuxilium's Xiaflex shows positive Phase 4 results
Auxilium announced interim data from its Phase 4 retreatment study evaluating Xiaflex in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord. Xiaflexis a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord, and has been granted Orphan Drug Designation in the U.S. by the FDA. 87% of recurrent contractures of metacarpophalangeal joints were successfully retreated. Patients showed an average 83% improvement in fixed flexion. 85% of recurrent contractures of proximal interphalangeal were successfully retreated. Retreatment with CCH was well tolerated.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
09:07 EDTAUXLOn The Fly: Pre-market Movers
Subscribe for More Information
07:32 EDTAUXLAuxilium announces positive data from Phase 2a study of CCH with cellulite
Subscribe for More Information
August 18, 2014
11:41 EDTAUXLCubist rises after report sparks takeover interest speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use